JP2011518760A5 - - Google Patents

Info

Publication number

JP2011518760A5

JP2011518760A5 JP2010532672A JP2010532672A JP2011518760A5 JP 2011518760 A5 JP2011518760 A5 JP 2011518760A5 JP 2010532672 A JP2010532672 A JP 2010532672A JP 2010532672 A JP2010532672 A JP 2010532672A JP 2011518760 A5 JP2011518760 A5 JP 2011518760A5

Authority

JP

Japan

Prior art keywords

composition

pbs

vaccine

αgalcer

lymphocytes

Prior art date

2008-08-29

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• LIXVHWQNKBIZBR-ICAJWQFTSA-N 1-O-(6-acetamido-6-deoxy-alpha-D-galactosyl)-N-[(15Z)-tetracos-15-enoyl]phytosphingosine Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CNC(C)=O)[C@H](O)[C@H](O)[C@H]1O LIXVHWQNKBIZBR-ICAJWQFTSA-N 0.000 claims description 12
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
• 239000000427 antigen Substances 0.000 claims description 4
• 102000036639 antigens Human genes 0.000 claims description 4
• 108091007433 antigens Proteins 0.000 claims description 4
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
• 229960005486 vaccine Drugs 0.000 claims 8
• 230000004913 activation Effects 0.000 claims 3
• 230000005847 immunogenicity Effects 0.000 claims 3
• 230000029662 T-helper 1 type immune response Effects 0.000 claims 2
• 230000003213 activating effect Effects 0.000 claims 2
• 230000028996 humoral immune response Effects 0.000 claims 2
• 238000007912 intraperitoneal administration Methods 0.000 claims 2
• 230000029069 type 2 immune response Effects 0.000 claims 2
• 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
• 230000004936 stimulating effect Effects 0.000 claims 1
• LIXVHWQNKBIZBR-IZJXYXLGSA-N (z)-n-[(3s,4r)-1-[(2s,4s,5r)-6-(acetamidomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihydroxyoctadecan-2-yl]tetracos-15-enamide Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(=O)NC([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1OC(CNC(C)=O)[C@H](O)[C@H](O)C1O LIXVHWQNKBIZBR-IZJXYXLGSA-N 0.000 description 8
• 241000699670 Mus sp. Species 0.000 description 7
• 230000007402 cytotoxic response Effects 0.000 description 6
• 210000004027 cell Anatomy 0.000 description 4
• 230000009089 cytolysis Effects 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 230000003013 cytotoxicity Effects 0.000 description 3
• 231100000135 cytotoxicity Toxicity 0.000 description 3
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 210000003141 lower extremity Anatomy 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 1
• 108010058846 Ovalbumin Proteins 0.000 description 1
• 230000005867 T cell response Effects 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 229940092253 ovalbumin Drugs 0.000 description 1